Introduction
============

Abnormalities of glucose metabolism are common in critically ill patients \[[@B1],[@B2]\] and are characterized by hyperglycemia \[[@B3]-[@B5]\], hypoglycemia \[[@B6],[@B7]\], and increased glucose variability \[[@B8],[@B9]\], each independently and additively associated with higher adjusted mortality rates \[[@B10]\]. Mechanisms of this adversity are not fully understood but may be related to increased susceptibility to sepsis, endothelial dysfunction, increased oxidative stress, and predisposition to cardiac arrhythmias \[[@B6],[@B11]\].

The extent to which hyperglycemia in critical illness should be corrected has been the focus of number of prospective studies \[[@B12]-[@B16]\] with conflicting results and remains the subject of an ongoing debate \[[@B17]\]. Possible explanations are different glucose targets in the control groups, different types of devices for blood-glucose measurement, as well as different nutritional strategies and varying levels of expertise with insulin therapy among the intensive care nurses \[[@B18]\].

Hypoglycemia is associated with adverse outcomes and may have negated any beneficial effect from intensive glucose control in those patients in whom target glucose levels were achieved.

Existing tools for achieving desired glucose levels range from sliding and dynamic scales, and paper-based protocols to computerized protocols that advise the nursing staff \[[@B19]\]. Safe implementation of insulin therapy requires accurate and frequent glucose measurements, but even hourly glucose measurements may fail to identify hypoglycemia during periods of rapid glucose change. Further, frequent sampling may be inconvenient for the patient and adds to the workload of the nursing staff \[[@B20]\].

Over the last decade, continuous subcutaneous glucose monitoring (CGM) has emerged as a valuable tool in the management of diabetes \[[@B21],[@B22]\]. A number of studies have investigated the accuracy of CGM devices in critical illness and have reported acceptable CGM performance \[[@B23]-[@B25]\], but the clinical efficacy and effectiveness of CGM devices in daily-life ICU practice is not yet established.

Availability of reliable continuous subcutaneous glucose monitoring has led to a rapid expansion of research into closed-loop insulin delivery, documenting superior performance compared with conventional pump therapy in type 1 diabetes \[[@B26]\].

The objective of the present study was to investigate the feasibility of automated closed-loop glucose control based on continuous subcutaneous glucose measurements in critically ill adults.

Materials and methods
=====================

Patients and study design
-------------------------

The study was an investigator-initiated, prospective single-center randomized controlled parallel-group open-label trial performed at the 24-bed Neurosciences Critical Care Unit (NCCU) at Addenbrooke\'s Hospital, Cambridge, UK, a tertiary trauma and neurosurgical referral center in the East of England with approximately 900 admissions per year (90% trauma or neurosciences patients). A separate research nurse was responsible for all study-related activities. Cambridge Central Research Ethics Committee approved the study.

Study participants were recruited from May 2012 to September 2012. All critically ill patients consecutively admitted to NCCU were screened for eligibility. Inclusion criteria were age 18 years and older, stay at NCCU expected of at least 48 hours, and arterial glucose level greater than 10.0 m*M*or already receiving insulin treatment, including preexisting diabetes. Exclusion criteria were diabetic ketoacidosis or hyperosmolar state, therapeutic hypothermia, known or suspected allergy to insulin, fatal organ failures, significant abnormalities of blood clotting, pregnancy, and treatment with external cardiac pacemaker.

Written informed consent/assent was obtained before enrolling a patient in the study, either from the patient, or, if patients lacked capacity, from the next of kin. Patients entered into the trial were randomized to an automated closed-loop or local sliding-scale insulin-therapy protocol by using the minimization method \[[@B27]\], implemented in the Minim program \[[@B28]\] to balance between group characteristics: Acute Physiology and Chronic Health Evaluation II (APACHE II) score, glucose at the time of randomization, body mass index, and preexisting diabetes. Randomization was carried out at the time of recruitment by the investigator by using a dedicated study laptop.

Common study procedures
-----------------------

Apart from glucose control, all other aspects of patient care, including nutritional management and treatment of hypoglycemia and hyperglycemia, were carried out according to local treatment protocols and were identical between treatment arms. Actrapid insulin (Novo Nordisk, Bagsværd, Denmark), in a concentration of 50 U in 50 ml of 0.9% saline, was used in both treatment arms. All study-related activities were carried out for a maximum period of 48 hours or until the end of the NCCU stay, whichever came first.

The study was terminated if the subject was moved out of NCCU for more than 2 hours.

Automated closed-loop therapy
-----------------------------

Subjects randomized to closed-loop therapy were treated by using an automated closed-loop system comprising (a) FreeStyle Navigator subcutaneous continuous glucose-monitoring system (Abbott Diabetes Care, Alameda, CA, USA), (b) a laptop computer running a model predictive control (MPC) algorithm, and (c) two Alaris CC Plus syringe pumps (CareFusion, Basingstoke, UK) (Figure [1](#F1){ref-type="fig"}). The CGM system uses CE-marked FreeStyle Navigator Transmitter, and a non-CE-marked investigational receiver device Navigator Companion (Abbott Diabetes Care), equivalent in its function and calibration algorithm to CE-marked Navigator Receiver with a 1-hour warm-up time \[[@B29]\]. The sensor was inserted in either the anterior abdominal wall or the upper arm. The user interface is shown in Figure [2](#F2){ref-type="fig"}.

![**Components of the closed-loop glucose-control system**.](cc12838-1){#F1}

![**User interface of the closed-loop system**.](cc12838-2){#F2}

We used a control algorithm based on the model predictive control approach \[[@B30]\], optimized and tuned *in silico*by using a computer-simulation environment validated for glucose control in the critically ill \[[@B31]\]. Every 5 minutes, the algorithm calculated insulin or, at low glucose values, 20% dextrose-infusion requirements based on minute-by-minute real-time sensor glucose values. The insulin and dextrose pumps were controlled automatically, and no manual intervention was required. The calculations used a compartment model of glucose kinetics \[[@B32]\], describing the effect of insulin on sensor glucose excursions. The algorithm was initialized by using patient\'s weight and adapted itself to a particular patient by updating two model parameters: a rapidly changing glucose flux correcting for errors in model-based predictions, and a slowly changing estimate of an insulin rate to maintain euglycemia. The individualized model forecasted plasma glucose excursions over a 1- to 1.5-hour prediction horizon when calculating the insulin rate and a 30- to 40-minute horizon when calculating the dextrose rate. Safety rules limited maximum insulin (50 U/h) and 20% dextrose (200 ml/h) delivery and prevented insulin delivery at sensor glucose below 1.2 m*M*of the target glucose level. Information about enteral or parenteral nutrition was not provided to the algorithm. The algorithm requested a reference glucose measurement every 1 to 6 hours (at a sensor level below 3.5 m*M*every 30 minutes); frequency depended on the deviation between sensor and reference glucose values. Reference glucose was used to recalibrate the sensor and to direct insulin and dextrose delivery when sensor levels were not available, such as during the 1-hour warm-up period. We used icuMPC algorithm version 1.0.6.

Local insulin therapy protocol
------------------------------

Subjects allocated to the local insulin therapy protocol followed the usual care of a paper-based intravenous insulin-administration protocol used in NCCU (Table [1](#T1){ref-type="table"}). When the patient\'s glucose control was deemed unsatisfactory, the bedside nurse could initiate a physician-prescribed alteration in the paper-based scale either to increase or to decrease the amount of insulin delivered for a given glucose level, as per usual practice. Similarly, insulin or dextrose boluses were prescribed at the discretion of the treating physician.

###### 

Local intravenous insulin titration protocol

  Blood glucose (m*M*)   Insulin infusion rates^a^(Units/hour)
  ---------------------- ---------------------------------------------
  20.0                   6.0, inform physician**^b^**
  17.1-20.0              4.0, inform physician**^b^**
  14.1-17.0              3.0, inform physician**^b^**
  11.1-14.0              2.5, inform physician**^b^**
  8.6-11.0               2.0, inform physician**^b^**if glucose \>10
  7.1-8.5                1.5
  5.6-7.0                1.0
  4.0-5.5                0.5
  \<4.0                  NIL, inform physician**^b^**

a50 Units Insulin Actrapid in 50 ml of 0.9% saline. bTarget glucose was 7 to 10 m*M*, and when the glucose was outside this target, hourly infusion rates were adjusted by the attending physician.

Reference glucose measurements
------------------------------

Arterial blood glucose measurements were made by using an on-site blood gas analyzer (Cobas b 221; Roche Diagnostics, Burgess Hill, UK) at hourly intervals. As previously described in the investigational arm, a subset of reference glucose values was provided as the algorithm dictated, but the remainder of the reference samples did not factor into patient management.

In the control arm, however, the hourly reference glucose values were available to the clinical team for insulin-dose adjustments.

Assessments and data collection
-------------------------------

Demographic and clinical characteristics, including APACHE II scores, were collected at study initiation. Patients were classified as having diabetes on the basis of medical history. Treatment with corticosteroids and inotropes was defined as treatment with these agents during any part of the study, including those subjects already taking these agents at study entry. From the time of randomization to the time of discharge from the ICU or 48 hours after randomization, whichever came first, we recorded all blood glucose measurements, insulin administration, type and volume of all enteral and parenteral nutrition and additional intravenous glucose administered, and corticosteroid and inotrope administration.

Statistical analysis
--------------------

Investigators agreed on the outcome measures and the analysis plan in advance. The primary outcome was the time spent in primary target-glucose range between 6.0 and 8.0 m*M*, as recorded by reference glucose measurements. Secondary efficacy outcomes were time spent with glucose levels between 4.0 and 10.0 m*M*, between 5.6 and 10.0 m*M*, above and below target ranges, mean and standard deviation of reference glucose, sensor accuracy metrics, and insulin-infusion rates. Safety end points included frequency and magnitude of significant hypoglycemic (\<3.0 m*M*and \<2.0 m*M*) and significant hyperglycemic (\>15 and 17 mM) episodes and other adverse events. Utility end points included the number of the reference glucose values requested by the algorithm and CGM availability.

As this was a feasibility study, no formal power calculations were performed. All analyses were performed on an intention-to-treat basis. An unpaired *t*test was used to compare normally distributed variables. Nonnormally distributed variables were compared by using a Mann-Whitney *U*test. Calculations were carried out by using SPSS Version 19 (IBM Software, Hampshire, UK). Outcomes were calculated with GStat software, Version 1.3 (University of Cambridge, UK). Values are given as mean (SD) or median (interquartile range). A *P*value \<0.05 was considered statistically significant.

Results
=======

Study participants
------------------

In total, 37 patients were screened. The next-of-kin refused consent in seven patients, and three patients failed inclusion/exclusion criteria. Of the 27 randomized subjects, two subjects left the intensive care unit within 24 hours of the study start, and one subject was initiated on therapeutic hypothermia within 24 hours. Efficacy but not safety data from these three subjects were excluded from the data analysis.

Twenty-four recruited subjects were analyzed (12 closed-loop and 12 local protocol); 21 (88%) subjects completed the intended 48 hours, whereas the remaining three (12%) subjects completed 24, 34, and 41 study hours because of early discharge from the NCCU. The baseline characteristics of the two groups were similar (Table [2](#T2){ref-type="table"}), with comparable APACHE Il scores, previous diabetes status, and body mass index. Of the 24 subjects, 11 (46%) had a history of preexisting diabetes. The majority (83%) of participants were already receiving insulin infusion at the time of study enrolment. The proportion of postsurgical patients was similar between two groups, whereas patients with major trauma were more common in the closed-loop group.

###### 

Baseline characteristics, nutritional intake, and corticosteroid and inotrope treatment of the study population

                                                        Local protocol (*n*= 12)   Automated closed-loop (*n*= 12)
  ----------------------------------------------------- -------------------------- ---------------------------------
  Age (years)                                           58.3 ± 12.5                62.8 ± 16.0
  Male sex (*n*/%)                                      9 (75%)                    9 (75%)
  White ethnicity                                       11 (92%)                   12 (100%)
  Weight (kg)                                           83.5 (80.0-89.2)           81.4 (62.5-97.5)
  BMI                                                   27.8 (25.9-30.8)           27.1 (26.4-31.4)
  APACHE II score at randomization                      11.2 ± 3.4                 12.9 ± 5.0
  Highest APACHE II score first 24 hours of admission   13.8 ± 5.0                 16.2 ± 5.4
  Time between admission and study start (days)         2 (1-7)                    1 (1-3)
  Previous diabetes                                     6 (50%)                    5 (42%)
  Insulin infusion at study start                       10 (83%)                   10 (83%)
  Reason for ICU admission                                                         
    Medical                                             1 (8%)                     3 (25%)
    After neurosurgery                                  4 (33%)                    4 (33%)
    Trauma                                              7 (58%)                    5 (42%)
  Total energy (kcal/hour)                              66.4 (17.2)                60.0 (18.4)
  Total CHO (g/hour)                                    7.9 (1.6)                  7.1 (2.2)
  Feeding interruptions/day                             1 (0-1.5)                  2 (0-2)
  Corticosteroid treatment                              3 (25%)                    5 (42%)
  Inotrope treatment                                    4 (33%)                    5 (42%)

Data shown are mean ± SD, median (interquartile range), or number (%). APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index.

Glucose control and insulin and dextrose administration
-------------------------------------------------------

The time spent in the primary target glucose range (6.0 to 8.0 m*M*) was significantly higher during closed-loop therapy (54.3% (44.1 to 72.8) versus 18.5% (0.1 to 39.9), closed-loop versus local protocol, *P*= 0.001, median (interquartile range), Table [3](#T3){ref-type="table"}). These differences were more pronounced during the first 24 hours, with a fourfold improvement of time spent in the target glucose range (59.4% (49.0 to 71.1) versus 14.5% (0.0 to 34.5), *P*= 0.001). These results persisted when the time was spent in a wider target range of 4.0 to 10.0 m*M*and 5.6 to 10.0 m*M*(Table [3](#T3){ref-type="table"}). Time spent at greater than 8.0 m*M*and 10.0 m*M*was significantly lower during closed-loop therapy. The cumulative distributions of glucose values during closed-loop therapy and the local protocol are shown in Figure [3](#F3){ref-type="fig"}, documenting comparable frequency of glucose levels \<5 m*M*. A sample 48-hour closed-loop study is shown in Figure [4](#F4){ref-type="fig"}.

###### 

Results based on reference glucose and insulin-infusion data

                                              Local protocol (*n*= 12)   Automated closed-loop (*n*= 12)   *P*
  ------------------------------------------- -------------------------- --------------------------------- -------
  Primary end point                                                                                        
  Time glucose in target (%) (6.0-8.0 m*M*)   18.5 (0.1-39.9)            54.3 (44.1-72.8)                  0.001
                                                                                                           
  Secondary end points                                                                                     
  Starting glucose (m*M*)                     10.8 (9.9-12.0)            10.0 (8.9-11.1)                   0.21
  Mean glucose (m*M*)                         9.1 (8.3-13.0)             7.9 (7.4-8.2)                     0.001
  Standard deviation of glucose (m*M*)        1.9 (0.8)                  1.3 (0.5)                         0.089
  Time spent at glucose levels (%)                                                                         
    4.0-10.0 m*M*                             73.2 (21.2-89.4)           93.3 (86.5-100.0)                 0.002
    5.6-10.0 m*M*                             73.2 (21.2-82.4)           92.2 (83.4-99.2)                  0.001
    \>8.0 m*M*                                78.4 (57.6-99.9)           39.0 (23.5-51.4)                  0.001
    \>10.0 m*M*                               26.8 (10.5-78.8)           6.7 (0-13.5)                      0.002
    \<6.0 m*M*                                0 (0-3.0)                  4.6 (3.1-8.3)                     0.028
    \<5.6 m*M*                                0 (0-0)                    0.7 (0-2.7)                       0.128
    \<4.0 m*M*                                0 (0-0)                    0 (0-0)                           NA
  Hypoglycemia                                                                                             
    Episodes \<4.0 m*M*                       None                       None                              
    Hypoglycemia treatments                   None                       None                              
  Hyperglycemia                                                                                            
    Number of subjects ≥15 m*M*               5 (42%)                    1 (8%)                            
    Number of subjects ≥17 m*M*               4 (33%)                    1 (8%)                            
    Episodes ≥15 m*M*                         11                         1                                 
    Episodes ≥17 m*M*                         13                         1                                 
  Insulin-infusion data                                                                                    
    Total units for 24 hours                  40.9 (34.9-101.4)          57.4 (40.0-112.2)                 0.478
     Hourly infusion rate                     1.7 (1.5-4.2)              2.4 (1.7-4.7)                     0.478
  Total dextrose infusion for 48 hours (g)    0.21 (0.0-5.2)             NA                                NA

Data shown are mean (SD) or median (interquartile range).

![**Cumulative distribution of reference glucose values obtained during closed-loop and local treatment protocol**. Dashed vertical lines indicate the primary study target range from 6.0 to 8.0 m*M*. Vertical fine dashed lines indicate the wider target from 4.0 to 10.0 m*M*.](cc12838-3){#F3}

![**An example of the 48-hour closed-loop study**. Darker red continuous line represents sensor glucose. Lighter red squares represent reference glucose measurements used for sensor calibration. Blue line represents insulin infusion. Thin red dashed lines indicate primary target. Dextrose infusion was not required in this study.](cc12838-4){#F4}

The mean glucose level was significantly lower during closed-loop therapy (7.9 (7.4 to 8.2) versus 9.1 (8.3 to 13.0) m*M; P*= 0.001) and more consistent among subjects in comparison to the local protocol (Figure [5](#F5){ref-type="fig"}). Glucose variability assessed by the standard deviation tended to be lower during the closed-loop therapy, without reaching statistical significance. Reference glucose profiles shown in Figure [6](#F6){ref-type="fig"} highlight differences between the two groups. The closed-loop system administered more insulin during the first study hours (Figure [6](#F6){ref-type="fig"}, bottom panel), but overall, no statistical difference was found in insulin infusion between the treatments (Table [3](#T3){ref-type="table"}). During closed-loop therapy, six (50%) of 12 patients received 20% dextrose, with a total amount less than 10 g per 24 hours, and one patient (8%) received 28 g dextrose per 24 hours.

![**Mean reference glucose per subject during closed-loop (*n*= 12) and local treatment protocol (*n*= 12)**. Horizontal black line indicates the mean reference glucose in each intervention arm.](cc12838-5){#F5}

![**Glucose and insulin values during infusion**. **Top panel:**Glucose profiles (median and interquartile range) during closed-loop and local treatment protocol. **Bottom panel:**Median insulin infusion rates during closed-loop and local treatment protocol. The dashed lines indicate the primary target range from 6 to 8 m*M*.](cc12838-6){#F6}

Nutrition and concomitant treatment
-----------------------------------

All but one patient received enteral nutrition, according to the local NCCU protocol. One patient received both enteral and parenteral nutrition. The number of calories and carbohydrates as well as the number of feeding interruptions per day was comparable between the two interventions (Table [2](#T2){ref-type="table"}). The proportion of patients treated with steroids or inotropes during the 48-hour study period was slightly higher during closed-loop therapy (Table [2](#T2){ref-type="table"}).

Safety
------

No hypoglycaemic events (\<4.0 m*M*) or other adverse events occurred in either group. The numbers of patients and the numbers of episodes with glucose \>15 and 17 m*M*were higher during treatment with the local protocol.

Utility assessment and sensor performance
-----------------------------------------

During closed-loop therapy, the number of reference glucose measurements requested by the control algorithm was 9.5 (9.0 to 14.0) during the first 24 hours and 7.0 (4.0 to 8.0) during the second 24 hours. This translated into an interval between sensor calibrations of 152 (105 to 160) and 205 (180 to 360) minutes during the first and second 24 hours, respectively. Sensor performance was good, with the median absolute deviation of 0.5 (0.3 to 1.0) m*M*, median relative absolute deviation of 7.0% (3.5 to 13.0), with 87.8% of sensor values within 20% of reference glucose. When the sensor levels were not available, the control algorithm directed insulin/dextrose delivery based on hourly reference glucose measurements, which were manually put into the algorithm. Overall, sensor unavailability for the entire 48-hour study period during closed-loop therapy was 25 (0 to 207) minutes. This translated to 5.6% of the closed-loop period, including the first hour of the study, during which the sensor was warming up. Excluding the mandatory first-hour sensor warm-up period, 3.4% of the closed-loop period used reference glucose values manually input. This occurred mostly during the first 10 hours of sensor use. Two subjects required replacement of sensor because of MRI scanning.

Discussion
==========

We documented that automated closed-loop glucose control, based on continuous subcutaneous glucose levels, is feasible and may significantly improve glucose levels without increasing the risk of hypoglycemia in critically ill adults. Compared with local intravenous sliding-scale therapy, closed-loop therapy increased up to fourfold the time spent in the target glucose range and reduced the time spent at higher glucose levels. Subjects treated with closed-loop therapy achieved consistent results, with a trend toward reduced glucose variability without requiring nurse interventions or decision making on insulin delivery.

Reflecting the current practice recommendations for glucose control in the intensive care unit \[[@B33],[@B34]\], we adopted a moderate glucose target of 6.0 to 8.0 m*M*rather than the tight glycemic range 4.4 to 6.1 m*M*of the Leuven and NICE-SUGAR studies. The upper limit of our target range is similar to recent consensus guidelines (\<8.3 m*M*) \[[@B35]\]. Based on our simulation work, we were confident of achieving a target between 6.0 and 8.0 m*M*without increasing the risk of hypoglycemia.

Subjects in the local-treatment protocol were treated with an intravenous sliding-scale protocol intended to maintain glucose in a safe target range of 7 to 10 m*M*without increasing the risk of hypoglycemia. We did not change the target range of the usual treatment for two reasons. First, we aimed to compare current local practice with a novel treatment; second, we could not guarantee patient safety by changing the target range of the sliding-scale protocol. The mean glucose level achieved during closed-loop control was 7.8 m*M*and was within the range associated with the lowest mortality in observational studies \[[@B5],[@B36]\]. Importantly, during the present study, closed-loop therapy achieved safe glucose levels without increasing the risk of hypoglycemia. Glucose variability, as measured by the standard deviation, tended to be lower during closed-loop without reaching statistical significance. Because both hypoglycemia and glucose variability have been associated with adverse outcomes, beneficial effects, apart from glucose lowering, may be achieved with closed-loop therapy.

Since the introduction of intensive insulin therapy, different algorithms and control systems aiming at effective and safe glucose control have been proposed \[[@B19]\]. These can range from written guidelines \[[@B12],[@B13]\] and protocols \[[@B37]-[@B40]\] to elementary \[[@B41],[@B42]\] and advanced computerized algorithms \[[@B43]-[@B48]\]. We used an advanced computer algorithm belonging to the family of model predictive control. The control algorithm and calibration strategy was optimized on a validated computer simulation environment for the critically ill \[[@B31]\] before study commencement to ensure favorable outcomes.

Our study is the first randomized controlled trial to evaluate fully automated closed-loop glucose control based on subcutaneous continuous glucose monitoring in critically ill patients. Another closed-loop study used subcutaneous glucose levels but was limited by a lack of a randomized design, a system that was able to control glucose in only one of five studied patients without manual interventions and relatively poor sensor performance, with 64% of values within 20% of reference glucose levels \[[@B49]\]. A third study, by using a closed-loop automated system in 208 Japanese intensive care patients, reported 88% of the time that glucose was in the range of 4.0 to 10.0 m*M*without hypoglycemia \[[@B50]\]. However, this was a retrospective observational study and used the STG-22 system (Nikkiso, Tokyo, Japan), which relies on continuous intravenous glucose measurements drawing 2 ml of blood per hour and is expensive \[[@B51]\], limiting its prolonged and wider use.

We initialized the closed-loop system by using approximate body weight and a reference glucose level. The system did not require information about nutritional intake and was able to respond to rapid changes in caloric and carbohydrate intake, even though a 15-minute lag exists between blood and Navigator sensor glucose levels \[[@B52]\]. When sensor glucose was unavailable during warm-up or for other technical reasons, the system used hourly arterial blood glucose without interruptions to insulin/dextrose delivery.

We increased accuracy of the subcutaneous continuous glucose monitor by calibrating with arterial blood glucose at a frequency higher than recommended by the manufacturer. During the first 24 hours, calibration occurred on average every 2.5 hours, and during the second 24 hours, every 3.5 hours. This is comparable with the present nurse workload. Benefits of subcutaneous glucose monitoring compared with intravenous measurements include reduced invasiveness, obviating the need for dedicated venous placement and a risk of contamination from dextrose or other medications that may interfere with glucose measurements. The risk of infection and thrombosis is lower with the subcutaneous route. The subcutaneous sensor placement was not associated with any complications.

The strengths of our study include the randomized controlled study design, the use of hourly arterial blood glucose to assess outcomes, comparability of the patient groups, and comparable nutrition and treatment modalities. Study limitations include a small sample size, a single-center study design involving a subspecialized patient population, and short study duration, which limits generalizability but does not affect the main study outcomes. The control achieved by using the sliding-scale protocol appears suboptimal and reflects the fear of hypoglycemia in the post-NICE-SUGAR era. Comparisons with other standard insulin-infusion protocols would be beneficial.

In conclusion, automated closed-loop therapy, based on subcutaneous continuous glucose measurements, is a safe and efficacious approach for glucose control in critically ill adults. Larger and longer-duration studies are warranted to assess system performance. Apart from providing a tangible treatment option, closed-loop systems may contribute important insights into the ongoing debate about glucose targets by providing the means to achieve uniform and safe outcomes in comparability studies.

Key messages
============

• Fully automated closed-loop glucose control based on subcutaneous sensor glucose is feasible.

• Closed-loop treatment provided safe, effective, and consistent glucose control without increasing the risk of hypoglycemia in a small group of patients over a 48-hour period.

• Closed-loop treatment was superior to a local sliding-scale treatment protocol.

• Nurse intervention is not required during closed-loop treatment, apart from calibrating a subcutaneous glucose monitor.

• Automated administration of dextrose augmented the ability of closed-loop treatment to avoid low glucose levels.
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